Evaluation of the efficacy,safety and pharmacoeconomics of micafungin and caspofungin respectively combined with trimethoprim-sulfamethoxazole in the treatment of Pneumocystis jirovecii pneumonia
Objective:To evaluate the efficacy,safety,and pharmacoeconomics of micafungin and caspo-fungin in combination with trimethoprim-sulfamethoxazole in the Pneumocystis jirovecii pneumonia treatment.Methods:We collected the clinical data of the patients with Pneumocystis jirovecii pneumo-nia admitted to Zhongnan Hospital of Wuhan University from January 2013 to April 2023.Of the pa-tients involved in this study,123 cases were treated with the combination of caspofungin and trime-thoprim-sulfamethoxazole(caspofungin group),and 27 cases were treated with the combination of mi-cafungin and trimethoprim-sulfamethoxazole(micafungin group).The efficacy,adverse reactions,and pharmacoeconomics between the two groups were compared.Results:The total effective rates were 70.37%in the micafungin group and 71.83%in the caspofungin group,respectively,without statisti-cally significant differences(P>0.05).The total incidence of adverse reactions was 18.52%in the micafungin group and 14.63%in the caspofungin group,respectively,without statistically significant differences too(P>0.05).But the daily medicine expenses showed a significant difference between the two groups,as a median of 384.0 yuan for the micafungin group versus 912.0 yuan for the caspo-fungin group,respectively,with a statistically significant difference(P<0.001).Conclusion:Mica-fungin and caspofungin in combination with trimethoprim-sulfamethoxazole are similar both in efficacy and adverse reactions when they were adopted in the treatment of Pneumocystis jirovecii pneumonia.From an economic perspective,micafungin is more advantageous when the efficacy and adverse reac-tions of the two are comparable.
万方数据
维普
